96 related articles for article (PubMed ID: 20421729)
1. Clonal selection in tamoxifen resistance.
Jin K; Sukumar S
Cancer Biol Ther; 2010 May; 9(9):725-7. PubMed ID: 20421729
[No Abstract] [Full Text] [Related]
2. A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.
Bogush EA; Ravcheeva AB; Bogush TA; Zabotina TN; Kadagidze ZG; Davydov MI
Dokl Biochem Biophys; 2007; 413():83-7. PubMed ID: 17546960
[No Abstract] [Full Text] [Related]
3. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
4. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol metabolism and resistance to tamoxifen.
Poirot M; Silvente-Poirot S; Weichselbaum RR
Curr Opin Pharmacol; 2012 Dec; 12(6):683-9. PubMed ID: 23063783
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells.
Tomková V; Sandoval-Acuña C; Torrealba N; Truksa J
Free Radic Biol Med; 2019 Nov; 143():510-521. PubMed ID: 31494243
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Fiorillo M; Sotgia F; Sisci D; Cappello AR; Lisanti MP
Oncotarget; 2017 Mar; 8(12):20309-20327. PubMed ID: 28411284
[TBL] [Abstract][Full Text] [Related]
10. Pak up your breast tumor--and grow!
Jordan VC
J Natl Cancer Inst; 2006 May; 98(10):657-9. PubMed ID: 16705113
[No Abstract] [Full Text] [Related]
11. Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin.
Delort L; Bougaret L; Cholet J; Vermerie M; Billard H; Decombat C; Bourgne C; Berger M; Dumontet C; Caldefie-Chezet F
Nutrients; 2019 Nov; 11(12):. PubMed ID: 31756890
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
13. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
Lash TL; Rosenberg CL
J Clin Oncol; 2010 Mar; 28(8):1273-5. PubMed ID: 20124162
[No Abstract] [Full Text] [Related]
14. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
16. Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition.
Jiang Y; Zhao X; Xiao Q; Liu Q; Ding K; Yu F; Zhang R; Zhu T; Ge G
J Mol Cell Biol; 2014 Aug; 6(4):352-4. PubMed ID: 24916398
[No Abstract] [Full Text] [Related]
17. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
18. MiR 221/222 as New Players in Tamoxifen Resistance.
Alamolhodaei NS; Behravan J; Mosaffa F; Karimi G
Curr Pharm Des; 2016; 22(46):6946-6955. PubMed ID: 27809747
[TBL] [Abstract][Full Text] [Related]
19. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
20. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
